Treating Tumors at Low Drug Doses Using an Aptamer-Peptide Synergistic Drug Conjugate.

Combination chemotherapy must strike a difficult balance between safety and efficacy. Current regimens suffer from poor therapeutic impact because drugs are given at their maximum tolerated dose (MTD), which compounds the toxicity risk and exposes tumors to non-optimal drug ratios. A modular framework has been developed that selectively delivers drug combinations at synergistic ratios via tumor-targeting aptamers for effective low-dose treatment. A nucleolin-recognizing aptamer was coupled to peptide scaffolds laden with precise ratios of doxorubicin (DOX) and camptothecin (CPT). This construct had an extremely low IC50 (31.9 nm) against MDA-MB-231 breast cancer cells in vitro, and exhibited in vivo efficacy at micro-dose injections (500 and 350 μg kg-1  dose-1 of DOX and CPT, respectively) that are 20-30-fold lower than their previously-reported MTDs. This approach represents a generalizable strategy for the safe and consistent delivery of combination drugs in oncology.

[1]  M. Levy,et al.  Targeted Delivery of Auristatin-Modified Toxins to Pancreatic Cancer Using Aptamers , 2017, Molecular therapy. Nucleic acids.

[2]  Jingwei Shao,et al.  A carrier-free dual-drug nanodelivery system functionalized with aptamer specific targeting HER2-overexpressing cancer cells. , 2017, Journal of materials chemistry. B.

[3]  Xiaojuan He,et al.  A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer , 2017, Nature Communications.

[4]  Matthew R. Levengood,et al.  Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates , 2016, Angewandte Chemie.

[5]  T. Przytycka,et al.  Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth , 2016, Molecular therapy. Nucleic acids.

[6]  J. Rossi,et al.  Aptamers as targeted therapeutics: current potential and challenges , 2016, Nature Reviews Drug Discovery.

[7]  Anil Kumar,et al.  Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance. , 2016, Biomaterials.

[8]  S. Mitragotri,et al.  DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[9]  Y. Zu,et al.  A unique aptamer-drug conjugate for targeted therapy of multiple myeloma , 2016, Leukemia.

[10]  C. Tung,et al.  Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia. , 2015, Biomaterials.

[11]  S. Mitragotri,et al.  Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[12]  M. Finn,et al.  Click chemistry in complex mixtures: bioorthogonal bioconjugation. , 2014, Chemistry & biology.

[13]  Y. Zu,et al.  Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy , 2014, Molecular therapy. Nucleic acids.

[14]  J. Katzenellenbogen,et al.  Selective Delivery of an Anticancer Drug with Aptamer-Functionalized Liposomes to Breast Cancer Cells in Vitro and in Vivo. , 2013, Journal of materials chemistry. B.

[15]  Weihong Tan,et al.  Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics , 2013, Proceedings of the National Academy of Sciences.

[16]  T. Siahaan,et al.  Peptide‐mediated targeted drug delivery , 2012, Medicinal research reviews.

[17]  W. Tan,et al.  Targeted Delivery of Chemotherapy Agents Using a Liver Cancer-Specific Aptamer , 2012, PloS one.

[18]  Liangfang Zhang,et al.  Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. , 2011, Molecular pharmaceutics.

[19]  Kevin Struhl,et al.  Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. , 2011, Cancer research.

[20]  Robert Langer,et al.  Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy , 2010, Proceedings of the National Academy of Sciences.

[21]  John O Trent,et al.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. , 2009, Experimental and molecular pathology.

[22]  J. Lee,et al.  Dose Escalation Methods in Phase I Cancer Clinical Trials , 2009, Journal of the National Cancer Institute.

[23]  Xiaoling Zhang,et al.  Molecular Assembly of an Aptamer–Drug Conjugate for Targeted Drug Delivery to Tumor Cells , 2009, Chembiochem : a European journal of chemical biology.

[24]  Ick Chan Kwon,et al.  Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[25]  Omid C Farokhzad,et al.  Co‐Delivery of Hydrophobic and Hydrophilic Drugs from Nanoparticle–Aptamer Bioconjugates , 2007, ChemMedChem.

[26]  L. Mayer,et al.  Optimizing combination chemotherapy by controlling drug ratios. , 2007, Molecular interventions.

[27]  Robert Langer,et al.  An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. , 2006, Angewandte Chemie.

[28]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[29]  M. Zamai,et al.  Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[30]  M. Slovak,et al.  PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.